CN-121975692-A - Fermented lactobacillus mucilaginosus RLF77 and application thereof

Abstract

The invention discloses a rabbit-derived fermented lactobacillus mucilaginosus RLF77 and application thereof. The strain is isolated from the intestinal tracts of weaned rabbits, and is preserved in China Center for Type Culture Collection (CCTCC) NO: M20252224. The strain has the excellent characteristics of being used as probiotics, being resistant to gastrointestinal tract environment, high in adhesion rate to intestinal epithelial cells, and capable of effectively inhibiting various pathogenic bacteria such as escherichia coli, salmonella and the like. Animal experiments show that the feeding of rabbit-sourced RLF77 strain can obviously improve the production performance of weaned rabbits, reduce diarrhea rate, improve survival rate and antioxidant capacity, and has better effect than non-rabbit-sourced probiotics. The invention provides a new strain resource for developing a green culture product for replacing antibiotics.

Inventors

• LI GUANGYU
• ZHAO MENGDI
• ZHANG YUANYUAN
• LI SHUXIAN

Assignees

• 青岛农业大学

Dates

Publication Date

20260505

Application Date

20260202

Claims (10)

1. 1. Lactobacillus mucilaginosus (Limosilactobacillus fermentum) RLF77 is preserved in China center for type culture Collection with a preservation number of CCTCC NO: M20252224.
2. 2. A probiotic formulation comprising lactobacillus mucilaginosus RLF77 according to claim 1.
3. 3. The probiotic preparation according to claim 2, characterized in that the probiotic preparation comprises said lactobacillus mucilaginosus RLF77 and/or fermentation products thereof.
4. 4. Use of lactobacillus mucilaginosus RLF77 according to claim 1 or a probiotic preparation according to claim 2 or 3 for the manufacture of a medicament for the prevention or treatment of diarrhea in weaned rabbits.
5. 5. Use of lactobacillus fermentum RLF77 according to claim 1 or a probiotic preparation according to claim 2 or 3 for the preparation of a product for the inhibition of pathogenic bacteria.
6. 6. The use according to claim 5, wherein the pathogenic bacteria comprise any of Listeria, escherichia coli, staphylococcus aureus, salmonella, or Pseudomonas aeruginosa.
7. 7. Use of lactobacillus fermentum RLF77 according to claim 1 or a probiotic preparation according to claim 2 or 3 for the preparation of an antioxidant product.
8. 8. A feed comprising lactobacillus fermentum RLF77 according to claim 1 or a probiotic formulation according to claim 2 or 3.
9. 9. A pharmaceutical composition comprising lactobacillus fermentum RLF77 according to claim 1 or a probiotic formulation according to claim 2 or 3.
10. 10. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition further comprises an adjuvant.

Description

Fermented lactobacillus mucilaginosus RLF77 and application thereof Technical Field The invention relates to the technical field of biology, in particular to lactobacillus mucilaginosus RLF77 and application thereof. Background The weaning period young rabbits have undeveloped digestive system, weak immune function, and the nutrition source is suddenly changed into solid diet from breast milk, so that the gastrointestinal digestive function is difficult to adapt at one time. Interruption of the supply of maternal antibodies and the immature rabbit autoimmune system have formed an "immune blank". Diarrhea is the most common and serious digestive tract disease in weaned rabbits, and intestinal flora disturbance is considered to be the main cause of diarrhea in the rabbits. At present, the feed is completely prohibited from adding growth-promoting medicine feed additives (except traditional Chinese medicines), so that the diarrhea problem during weaning of young rabbits is increasingly prominent. For young rabbits, the post-weaning period is a critical window period for establishing digestive function and immune response capacity. The intestinal flora is stabilized through the intervention of probiotics, and the method is a potential effective strategy for guaranteeing the intestinal health of the young rabbits and replacing antibiotics. However, in practical application, existing probiotic products generally have obvious problems of strain specificity and host adaptability, and are specifically expressed in the following two aspects: 1. The non-host probiotics have unstable effect and poor colonization capability. Most probiotics in the market at present are not derived from rabbit bodies, and the effect of the probiotics in the intestinal tracts of young rabbits is obviously different. The root is that the exogenous strains are difficult to adapt to the special intestinal microenvironment of rabbits, have weak adhesion and colonization capability, and cannot form stable and efficient functional interaction with hosts and the primary flora thereof, so that the probiotics have large fluctuation. 2. Host-derived probiotics are not developed enough and lack of efficient special strains. At present, rabbit-source probiotics which are screened by a system, have definite functions and can realize industrialized application and are specially used for treating diarrhea of rabbits are very rare, and mature technology and market supply are not formed. Therefore, the prior art fails to provide a special probiotic bacterial strain which can effectively break through the host barrier, realize efficient colonization in the intestinal tract of rabbits and stably exert the anti-diarrhea function. In view of this, the present invention has been made. Disclosure of Invention In order to solve the problems, the invention successfully separates a strain of fermented lactobacillus mucilaginosus from the intestinal tracts of healthy weaned rabbits. The development of the host-source probiotics is expected to provide a safer and more efficient solution for targeted prevention and treatment of diarrhea in weaning period of young rabbits and promotion of healthy growth of the young rabbits. In order to achieve the above object of the present invention, the following technical solutions are specifically adopted: Lactobacillus mucilaginosus (Limosilactobacillus fermentum) RLF77 is preserved in China center for type culture Collection with a preservation number of CCTCC NO: M20252224. The lactobacillus mucilaginosus RLF77 is a novel probiotic strain isolated from the intestinal tract of weaned rabbits. The strain is preserved in China Center for Type Culture Collection (CCTCC) No. M20252224, and the preservation date is 2025, 10 months and 16 days. The strain has excellent probiotic characteristics, shows strong tolerance in-vitro simulated gastrointestinal tract environment, has a survival rate of 88.56% after being treated for 3 hours under the condition of pH 2.5, has a survival rate of 75.78% after being treated in 0.3% bile salt, and has good cell adhesion capability. The core function of the anti-oxidant is that the anti-oxidant can effectively inhibit various common intestinal pathogens including escherichia coli and salmonella, and has anti-oxidant activity. Animal experiments prove that the rabbit-sourced RLF77 strain can obviously improve the production performance of weaned rabbits, reduce diarrhea rate, improve survival rate and oxidation resistance, and has better effect than non-rabbit-sourced probiotics. Therefore, the strain has important application value in replacing feeding antibiotics, guaranteeing intestinal health of young rabbits and promoting green cultivation. A probiotic formulation comprising said lactobacillus mucilaginosus RLF77. The invention provides a probiotic preparation comprising lactobacillus viscosus RLF77 from rabbit source. The preparation core strain RLF77 is separated from the intestinal tracts